A Case Report of Posttransplant Lymphoproliferative Disorder After AstraZeneca Coronavirus Disease 2019 Vaccine in a Heart Transplant Recipient.

Authors :: Tang WR
Hsu CW
Lee CC
Huang WL
Lin CY
Hsu YT
Chang C
Tsai MT
Hu YN
Hsu CH
Chen PL
Chow NH
Roan JN
Source :: Transplantation proceedings [Transplant Proc] 2022 Jul-Aug; Vol. 54 (6), pp. 1575-1578. Date of Electronic Publication: 2021 Sep 30.
Publication Year :: 2022
Abstract: We report a case of a heart transplant recipient who presented with a rapidly growing Epstein-Barr virus (EBV)-positive, diffuse large B-cell lymphoma 7 days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. Because of the atypical radiologic presentation, the initial tentative diagnosis was a mediastinal abscess. This observation indicates a potential risk of EBV reactivation after coronavirus disease 2019 (COVID-19) vaccination, which might lead to or aggravate the presentation of posttransplant lymphoproliferative disorder in transplantation patients. Transplant surgeons should be aware of the potential immunomodulatory effects of the COVID-19 vaccination.<br /> (Copyright © 2021 Elsevier Inc. All rights reserved.)

Subjects :: Humans
Herpesvirus 4, Human
ChAdOx1 nCoV-19 adverse effects
COVID-19 prevention & control
Epstein-Barr Virus Infections complications
Epstein-Barr Virus Infections diagnosis
Heart Transplantation
Lymphoproliferative Disorders chemically induced
Lymphoproliferative Disorders diagnosis

Full Text Access

Tools